REFERENCES
1. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143:e254-743.
2. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145:e153-639.
3. Pu L, Wang L, Zhang R, Zhao T, Jiang Y, Han L. Projected global trends in ischemic stroke incidence, deaths and disability-adjusted life years from 2020 to 2030. Stroke. 2023;54:1330-9.
4. Iadecola C, Buckwalter MS, Anrather J. Immune responses to stroke: mechanisms, modulation, and therapeutic potential. J Clin Invest. 2020;130:2777-88.
5. Mokin M, Primiani CT, Siddiqui AH, Turk AS. ASPECTS (Alberta Stroke Program Early CT Score) measurement using hounsfield unit values when selecting patients for stroke thrombectomy. Stroke. 2017;48:1574-9.
6. Gasull T, Arboix A. Molecular Mechanisms and Pathophysiology of Acute Stroke: Emphasis on Biomarkers in the Different Stroke Subtypes. Int J Mol Sci. 2022;23:9476.
7. Rathburn CM, Mun KT, Sharma LK, Saver JL. TOAST stroke subtype classification in clinical practice: implications for the get with the guidelines-stroke nationwide registry. Front Neurol. 2024;15:1375547.
8. Nam KW, Kwon HM, Lee YS. Clinical significance of D-dimer levels during acute period in ischemic stroke. Thromb J. 2023;21:55.
9. Jiménez MC, Rexrode KM, Glynn RJ, Ridker PM, Gaziano JM, Sesso HD. Association between high-sensitivity C-reactive protein and total stroke by hypertensive status among men. J Am Heart Assoc. 2015;4:e002073.
10. Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128:1728-46.
11. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165:2479-84.
12. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31.
13. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837-42.
14. Durrani Y, Gerstl JVE, Murphy D, et al. Prospective validation of glial fibrillary acidic protein, d‐dimer, and clinical scales for acute large‐vessel occlusion ischemic stroke detection. SVIN. 2024;4:e001304.
15. Akbar M, Damayanti F, Tammasse J, Bintang AK, Aulina S, Soraya GV. Plasma D-dimer as a biomarker for the early classification of common acute ischemic stroke subtypes in Indonesia. Egypt J Neurol Psychiatry Neurosurg. 2023;59:720.
16. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708-18.
17. Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet. 2019;394:139-47.
18. Jickling GC, Stamova B, Ander BP, et al. Profiles of lacunar and nonlacunar stroke. Ann Neurol. 2011;70:477-85.
19. Vaughn A, Thompson D, Prodan CI. Do Commonly Obtained Laboratory Data Differ between Lacunar and Non-Lacunar Strokes in the Acute Setting? Neurology. 2013;80:P03.185.
20. Armario P, Gomez-Choco M, Garcia-Sanchez SM, et al. Differences in biomarkers levels and brachial and central blood pressure during the acute phase of stroke between lacunar and other ischemic strokes subtypes. J Hypertens. 2018;36:e27.
21. Arboix A, Massons J, García-Eroles L, Targa C, Comes E, Parra O. Clinical predictors of lacunar syndrome not due to lacunar infarction. BMC Neurol. 2010;10:31.
22. Zhao YH, Gao H, Pan ZY, et al. Prognostic value of NT-proBNP after ischemic stroke: a systematic review and meta-analysis of prospective cohort studies. J Stroke Cerebrovasc Dis. 2020;29:104659.
23. Sanchez JD, Martirosian RA, Mun KT, et al. Temporal patterning of neurofilament light as a blood-based biomarker for stroke: a systematic review and meta-analysis. Front Neurol. 2022;13:841898.
24. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304-51.
26. Kim TJ, Jung JW, Kim YJ, Yoon BW, Han D, Ko SB. Proteomic analyses of clots identify stroke etiologies in patients undergoing endovascular therapy. CNS Neurosci Ther. 2025;31:e70340.
27. Doche E, Sulowski C, Guigonis JM, et al. How clot composition influences fibrinolysis in the acute phase of stroke: a proteomic study of cerebral thrombi. Stroke. 2024;55:1818-29.
28. Dawson J, Walters M, Delles C, Mischak H, Mullen W. Urinary proteomics to support diagnosis of stroke. PLoS One. 2012;7:e35879.
29. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13:263-9.
30. Karmelić I, Rubić I, Starčević K, et al. Comparative targeted metabolomics of ischemic stroke: thrombi and serum profiling for the identification of stroke-related metabolites. Biomedicines. 2024;12:1731.
31. Papadopoulos A, Palaiopanos K, Björkbacka H, et al. Circulating interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of prospective studies. Neurology. 2022;98:e1002-12.
32. Blecharz-Lang KG, Wagner J, Fries A, et al. Interleukin 6-mediated endothelial barrier disturbances can be attenuated by blockade of the IL6 receptor expressed in brain microvascular endothelial cells. Transl Stroke Res. 2018;9:631-42.
33. Xue Y, Zeng X, Tu WJ, Zhao J. Tumor necrosis factor-α: the next marker of stroke. Dis Markers. 2022;2022:2395269.
34. Xu G, Dong F, Su L, et al. The role and therapeutic potential of nuclear factor κB (NF-κB) in ischemic stroke. Biomed Pharmacother. 2024;171:116140.
35. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke. 2007;38:1229-37.
36. Georgakis MK, Malik R, Björkbacka H, et al. Circulating monocyte chemoattractant protein-1 and risk of stroke: meta-analysis of population-based studies involving 17 180 individuals. Circ Res. 2019;125:773-82.
37. Xu Q, Liu Y, Tian X, et al. Monocyte chemoattractant protein-1, inflammatory biomarkers, and prognosis of patients with ischemic stroke or transient ischemic attack: fndings from a nationwide registry study. J Am Heart Assoc. 2024;13:e035820.
38. Li J, Wang Y, Lin J, et al. Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke. 2015;46:1990-2.
39. Simak J, Gelderman MP, Yu H, Wright V, Baird AE. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost. 2006;4:1296-302.
40. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31:27-33.
41. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6:82-90.
42. Furuki K, Adachi H, Matsuoka H, et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis. 2007;191:206-10.
43. Willeit P, Freitag DF, Laukkanen JA, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015;4:e001833.
45. Richard S, Lagerstedt L, Burkhard PR, Debouverie M, Turck N, Sanchez JC. E-selectin and vascular cell adhesion molecule-1 as biomarkers of 3-month outcome in cerebrovascular diseases. J Inflamm. 2015;12:61.
46. Foley KE, Wilcock DM. Soluble biomarkers of cerebrovascular pathologies. Stroke. 2024;55:801-11.
47. Tanne D, Haim M, Boyko V, et al. Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort. Stroke. 2002;33:2182-6.
48. Wang M, Zhang Z, Liu D, et al. Soluble adhesion molecules and functional outcome after ischemic stroke: A Mendelian randomization study. J Stroke Cerebrovasc Dis. 2023;32:107136.
49. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536-44.
50. Chen F, Han Y, Hu H, Guo Y, Deng Z, Liu D. Nonlinear association of fibrinogen levels with functional prognosis in patients with acute ischemic stroke: a prospective cohort study. BMC Neurol. 2024;24:163.
51. Swarowska M, Polczak A, Pera J, Klimkowicz-Mrowiec A, Slowik A, Dziedzic T. Hyperfibrinogenemia predicts long-term risk of death after ischemic stroke. J Thromb Thrombolysis. 2014;38:517-21.
52. Lee SJ, Hong JM, Lee SE, et al. Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes. BMC Neurol. 2017;17:101.
53. Mehta V, Sharma A, Jyoti D, et al. Fibrinogen as a predictor of early neurological deterioration in acute ischemic stroke - evidence from the Indian population. J Cent Nerv Syst Dis. 2023;15:11795735231156349.
54. Li X, Du H, Song Z, et al. Association between fibrinogen levels and stroke-associated pneumonia in acute ischemic stroke patients. BMC Neurol. 2024;24:256.
55. Harris S, Rasyid A, Kurniawan M, Mesiano T, Hidayat R. Association of high blood homocysteine and risk of increased severity of ischemic stroke events. Int J Angiol. 2019;28:34-8.
56. Pinzon RT, Wijaya VO, Veronica V. The role of homocysteine levels as a risk factor of ischemic stroke events: a systematic review and meta-analysis. Front Neurol. 2023;14:1144584.
57. Kwon HM, Lee YS, Bae HJ, Kang DW. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke. 2014;45:871-3.
58. Rabelo NN, Telles JPM, Pipek LZ, et al. Homocysteine is associated with higher risks of ischemic stroke: a systematic review and meta-analysis. PLoS One. 2022;17:e0276087.
59. Huang M, Xu S, Zhou M, et al. Lysophosphatidylcholines and phosphatidylcholines as biomarkers for stroke recovery. Front Neurol. 2022;13:1047101.
60. Havulinna AS, Sysi-Aho M, Hilvo M, et al. Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort. Arterioscler Thromb Vasc Biol. 2016;36:2424-30.
61. Paul JF, Ducroux C, Correia P, et al. Serum glial fibrillary acidic protein in acute stroke: feasibility to determine stroke-type, timeline and tissue-impact. Front Neurol. 2024;15:1470718.
62. Guo ZN, Qu Y, Abuduxukuer R, et al. Serum GFAP and UCH-L1 levels for the assessment of the absence of hemorrhagic transformation: a multicenter prospective cohort study. Stroke. 2025;56:22-9.
63. Luger S, Witsch J, Dietz A, et al. Glial fibrillary acidic protein serum levels distinguish between intracerebral hemorrhage and cerebral ischemia in the early phase of stroke. Clin Chem. 2017;63:377-85.
64. Ferrari F, Rossi D, Ricciardi A, et al. Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients. J Cereb Blood Flow Metab. 2023;43:1601-11.
65. Pujol-Calderón F, Zetterberg H, Portelius E, et al. Prediction of outcome after endovascular embolectomy in anterior circulation stroke using biomarkers. Transl Stroke Res. 2022;13:65-76.
66. Pandey A, Shrivastava AK, Saxena K. Neuron specific enolase and c-reactive protein levels in stroke and its subtypes: correlation with degree of disability. Neurochem Res. 2014;39:1426-32.
67. Choi KH, Kim JH, Kim JM, et al. d-dimer Level as a predictor of recurrent stroke in patients with embolic stroke of undetermined source. Stroke. 2021;52:2292-301.
68. Ahmad A, Islam Z, Manzoor Ahmad S, et al. The correlation of D-dimer to stroke diagnosis within 24 hours: a meta-analysis. J Clin Lab Anal. 2022;36:e24271.
69. Zhu Z, He Y, Shi M, et al. Plasma osteopontin levels and adverse clinical outcomes after ischemic stroke. Atherosclerosis. 2021;332:33-40.
70. Ozaki S, Kurata M, Kumon Y, et al. Plasma thrombin-cleaved osteopontin as a potential biomarker of acute atherothrombotic ischemic stroke. Hypertens Res. 2017;40:61-6.
71. Sørensen SS, Nygaard AB, Carlsen AL, Heegaard NHH, Bak M, Christensen T. Elevation of brain-enriched miRNAs in cerebrospinal fluid of patients with acute ischemic stroke. Biomark Res. 2017;5:24.
72. He XW, Shi YH, Liu YS, et al. Increased plasma levels of miR-124-3p, miR-125b-5p and miR-192-5p are associated with outcomes in acute ischaemic stroke patients receiving thrombolysis. Atherosclerosis. 2019;289:36-43.
73. Montaner J, Mendioroz M, Delgado P, et al. Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: the S100B/RAGE pathway. J Proteomics. 2012;75:4758-65.
74. Foerch C, Otto B, Singer OC, et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke. 2004;35:2160-4.
75. Bitsch A, Horn C, Kemmling Y, et al. Serum tau protein level as a marker of axonal damage in acute ischemic stroke. Eur Neurol. 2002;47:45-51.
76. Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187-90.
77. Srisujikul P, Thiankhaw K, Tanprawate S, et al. Serum NT-proBNP level for predicting functional outcomes after acute ischemic stroke. Sci Rep. 2023;13:13903.
78. Di Castelnuovo A, Veronesi G, Costanzo S, et al. NT-proBNP (N-terminal Pro-B-type natriuretic peptide) and the risk of stroke. Stroke. 2019;50:610-7.
79. Scheitz JF, Lim J, Broersen LHA, et al. High-sensitivity cardiac troponin T and recurrent vascular events after first ischemic stroke. J Am Heart Assoc. 2021;10:e018326.
80. Negishi K, Hoshide S, Shimpo M, Kanegae H, Kario K. Growth differentiation factor-15 predicts death and stroke event in outpatients with cardiovascular risk factors: the J-HOP study. J Am Heart Assoc. 2021;10:e022601.
81. Tiedt S, Duering M, Barro C, et al. Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke. Neurology. 2018;91:e1338-47.
82. Yilmaz G, Granger DN. Leukocyte recruitment and ischemic brain injury. Neuromolecular Med. 2010;12:193-204.
83. Yilmaz G, Alexander JS. Impaired peripheral vascular function following ischemic stroke in mice: potential insights into blood pressure variations in the post-stroke patient. Pathophysiology. 2024;31:488-501.
84. Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J Cereb Blood Flow Metab. 2015;35:888-901.
85. Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006;113:2105-12.
86. Suh B, Shin DW, Kwon HM, et al. Elevated neutrophil to lymphocyte ratio and ischemic stroke risk in generally healthy adults. PLoS One. 2017;12:e0183706.
87. Liu D, Fan X, Wang J, et al. Association between NLR, MLR and stroke incidence, all-cause mortality among low-income aging populations: a prospective cohort study. J Inflamm Res. 2025;18:5715-26.
88. Lu M, Zhang Y, Liu R, He X, Hou B. Predictive value of neutrophil to lymphocyte ratio for ischemic stroke in patients with atrial fibrillation: A meta-analysis. Front Neurol. 2022;13:1029010.
89. Curtis AM, Edelberg J, Jonas R, et al. Endothelial microparticles: sophisticated vesicles modulating vascular function. Vasc Med. 2013;18:204-14.
90. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res. 2009;335:143-51.
91. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Bidot CJ, Ahn YS. Endothelial microparticles (EMP) as vascular disease markers. Adv Clin Chem. 2005;39:131-57.
92. Lugo-Gavidia LM, Burger D, Matthews VB, et al. Role of microparticles in cardiovascular disease: implications for endothelial dysfunction, thrombosis, and inflammation. Hypertension. 2021;77:1825-44.
93. Maglinger B, Sands M, Frank JA, et al. Intracranial VCAM1 at time of mechanical thrombectomy predicts ischemic stroke severity. J Neuroinflammation. 2021;18:109.
94. Huang Y, Wang Z, Huang ZX, Liu Z. Biomarkers and the outcomes of ischemic stroke. Front Mol Neurosci. 2023;16:1171101.
95. Law SH, Chan HC, Ke GM, et al. Untargeted lipidomic profiling reveals lysophosphatidylcholine and ceramide as atherosclerotic risk factors in apolipoprotein E knockout mice. Int J Mol Sci. 2023;24:6956.
96. Azizkhanian I, Sheth SA, Iavarone AT, Lee S, Kakarla V, Hinman JD. Plasma lipid profiling identifies biomarkers of cerebral microvascular disease. Front Neurol. 2019;10:950.
97. Foerch C, Niessner M, Back T, et al. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem. 2012;58:237-45.
98. Wunderlich MT, Wallesch CW, Goertler M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci. 2004;227:49-53.
99. Brea D, Sobrino T, Blanco M, et al. Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke. Clin Chem Lab Med. 2009;47:1513-8.
100. Mochetti MM, Silva EGP, Correa AAF, et al. Neuron-specific enolase at admission as a predictor for stroke volume, severity and outcome in ischemic stroke patients: a prognostic biomarker review. Sci Rep. 2024;14:2688.
101. Yilmaz G, Alexander JS, Erkuran Yilmaz C, Granger DN. Induction of neuro-protective/regenerative genes in stem cells infiltrating post-ischemic brain tissue. Exp Transl Stroke Med. 2010;2:11.
102. Tsai PC, Liao YC, Wang YS, Lin HF, Lin RT, Juo SH. Serum microRNA-21 and microRNA-221 as potential biomarkers for cerebrovascular disease. J Vasc Res. 2013;50:346-54.
103. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta. 2004;342:1-12.
104. Cario A, Berger CL. Tau, microtubule dynamics, and axonal transport: New paradigms for neurodegenerative disease. Bioessays. 2023;45:e2200138.
105. Everdingen KJ, van der Grond J, Kappelle LJ, Ramos LM, Mali WP. Diffusion-weighted magnetic resonance imaging in acute stroke. Stroke. 1998;29:1783-90.
106. Bang OY, Saver JL, Buck BH, et al. Impact of collateral flow on tissue fate in acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2008;79:625-9.
107. Oppenheim C, Samson Y, Manaï R, et al. Prediction of malignant middle cerebral artery infarction by diffusion-weighted imaging. Stroke. 2000;31:2175-81.
108. Demeestere J, Wouters A, Christensen S, Lemmens R, Lansberg MG. Review of perfusion imaging in acute ischemic stroke: from time to tissue. Stroke. 2020;51:1017-24.
109. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165-74.
110. Sorensen AG, Copen WA, Ostergaard L, et al. Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time. Radiology. 1999;210:519-27.
111. Smith CJ, Emsley HC, Gavin CM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004;4:2.
112. Hofmeijer J, van Putten MJ. Ischemic cerebral damage: an appraisal of synaptic failure. Stroke. 2012;43:607-15.
113. Bustamante A, Simats A, Vilar-Bergua A, García-Berrocoso T, Montaner J. Blood/Brain biomarkers of inflammation after stroke and their association with outcome: from C-reactive protein to damage-associated molecular patterns. Neurotherapeutics. 2016;13:671-84.
114. Goyal N, Tsivgoulis G, Chang JJ, et al. Admission neutrophil-to-lymphocyte ratio as a prognostic biomarker of outcomes in large vessel occlusion strokes. Stroke. 2018;49:1985-7.
115. Li Y, Chen K, Wang L, et al. Values of lymphocyte-related ratios in predicting the clinical outcome of acute ischemic stroke patients receiving intravenous thrombolysis based on different etiologies. Front Neurol. 2025;16:1542889.
116. Telec M, Frydrychowicz M, Kazmierski R, et al. Circulating CD4+, CD8+, and double-negative T cells in ischemic stroke and stroke-associated infection: a prospective case-control study. Front Cell Neurosci. 2025;19:1547905.
117. Fu Y, Liu Q, Anrather J, Shi FD. Immune interventions in stroke. Nat Rev Neurol. 2015;11:524-35.
118. Akhtar N, Abid FB, Kamran S, et al. Characteristics and comparison of 32 COVID-19 and Non-COVID-19 ischemic strokes and historical stroke patients. J Stroke Cerebrovasc Dis. 2021;30:105435.
119. Hochrainer K, Yang W. Stroke proteomics: from discovery to diagnostic and therapeutic applications. Circ Res. 2022;130:1145-66.
120. Li Q, Zhang X, Zhang Y, et al. Using proteomic biomarkers to estimate acute ischaemic stroke onset time. Commun Med. 2025;5:183.
121. Li Q, Zhang X, Zhang Y, et al. Metabolomic biomarkers could be molecular clocks in timing stroke onset. Sci Rep. 2025;15:21645.
122. Li X, Li L, Si X, et al. The regulatory roles of circular RNAs via autophagy in ischemic stroke. Front Neurol. 2022;13:963508.
123. Lehmann ALCF, Alfieri DF, de Araújo MCM, et al. Immune-inflammatory, coagulation, adhesion, and imaging biomarkers combined in machine learning models improve the prediction of death 1 year after ischemic stroke. Clin Exp Med. 2022;22:111-23.
124. Ruksakulpiwat S, Zhou W, Phianhasin L, et al. A systematic review and meta-analysis assessing the accuracy of blood biomarkers for the diagnosis of ischemic stroke in adult and elderly populations. eNeuro. 2024;11:ENEURO.0302-24.2024.
125. American Heart Association. Public policy considerations of novel cardiovascular disease and stroke blood-based biomarkers; Dallas, TX: American Heart Association; 2024. Available from: https://www.heart.org/en/-/media/Files/About-Us/Policy-Research/Policy-Positions/Heart-Stroke-Research/Novel-CVD-Stroke-Biomarkers.pdf?sc_lang=en [Last accessed on 15 Aug 2025].
